Prihlásiť sa Zaregistrujte sa zadarmo

Účtovná hodnota akcie spoločnosti Starpharma

Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Starpharma?

Hodnota metriky Účtovná hodnota akcie spoločnosti Starpharma Holdings Limited je 0.01

Aká je definícia metriky Účtovná hodnota akcie?

Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.

The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.

The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.

Účtovná hodnota akcie spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Starpharma

Čomu sa venuje spoločnosť Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Starpharma



  • Hodnota metriky Účtovná hodnota akcie spoločnosti Mundoro Capital je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Renavotio Inc je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Novan Inc je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Babylon Pump & Power je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Kitov Pharma Ltd je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Atari SA je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Starpharma je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Bold Ventures je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti International Business Settlement je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti 4DS Memory je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Rover Metals je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Vitality Biopharma je 0.01
  • Hodnota metriky Účtovná hodnota akcie spoločnosti Galore Resources je 0.01